HAVCR2 and non-small cell lung carcinoma: PD-1 blockade therapy has been shown to increase the expression of other immune checkpoints, such as TIM-3, Hammerman and colleagues discovered that prolonged exposure to PD-1 blockade antibodies escalates TIM-3 expression in non-small cell lung cancer patients (153, 154).